Kearney’s Dr Stephanie Allen: Health systems must pivot toward longevity and lifelong health

She discusses impactful healthcare innovations, partnerships, leadership qualities for scaling across markets, policy engagement, and preparing health systems for demographic shifts.

The healthcare industry is moving away from reactive care towards a longevity-focused model that prioritises equitable access. This transformation is particularly dynamic within Asia Pacific, because whilst it faces unique challenges in affordability and ageing populations, it is also becoming a nest for innovation where strategic funding and cross-border collaborations are setting new benchmarks for the rest of the world.

Kearney’s Senior Advisor, Dr Stephanie Allen, embodies the multi-dimensional expertise needed to succeed in this environment, bringing over 23 years of healthcare leadership to the panel. As the CEO of JumpStart Fertility, she is also at the literal frontier of reproductive science, tackling the biological impacts of ageing.

At the same time, her profile seamlessly bridges gaps between understanding complex global challenges and charting a clear path for organisations. Whether through her role as a Global Leader at Eucalyptus Health or her extensive work advising Boards and C-suite leaders, she has built a career on cultivating high-stakes partnerships and motivating teams to achieve essential outcomes.

As a judge for the Healthcare Asia Awards 2026, Dr Allen explores the future of healthcare innovation, leadership, and policy, especially which breakthroughs in reproductive ageing are going to have the biggest impact, which partnership models best scale innovations across APAC, and how innovators can engage policymakers responsibly. She also provides insights on how health systems should prepare for demographic shifts like ageing populations and declining fertility.

Based on your experience, what breakthroughs in addressing reproductive ageing do you believe will have the greatest clinical and societal impact over the few years?

Women everywhere deserve more choices for healthy reproductive ageing. Today, many women are pursuing careers or personal goals through their twenties, but biology hasn’t caught up with modern life. Fertility declines sharply by the late thirties, and by 38, the chance of natural conception drops significantly.

As the CEO of a company pioneering new fertility science, I see enormous potential in next‑generation cellular‑level interventions that can restore oocyte quality and improve the likelihood of a healthy birth. These breakthroughs matter not just for women and families — they’re critical for societies across APAC where birth rates are falling and ageing populations threaten future workforces and economic stability.

What partnership models have you seen work best in scaling healthcare innovations across multiple APAC markets?

APAC is one of the most diverse regions in the world — different languages, regulations, funding systems, and cultural expectations. The models that work best pair deep local expertise with regional or global scale. Local clinical partners bring cultural understanding and regulatory insight, whilst larger partners contribute digital platforms, capital, and distribution. Shared‑risk commercial structures tend to grow fastest because everyone is equally invested in the outcome.

How can healthcare innovators proactively engage policy makers to shape regulation whilst maintaining public trust?

It must be a genuine two‑way partnership. Too often, regulators struggle to keep pace with innovation — AI in healthcare is a good example — and innovators don’t always appreciate the need for clear guardrails. Transparency, openness, and mutual respect are essential.

A strong recent example is Australia’s National Framework for Digital Health Standards, announced in February 2026, where industry, government, and regulators collaborated to develop standards before formal policy existed. Initiatives like this show how co‑design builds both effective regulation and public confidence.

What leadership traits are most critical when scaling healthcare organisations across diverse markets?

Adaptability, humility, and clarity of purpose matter most. Great leaders in APAC listen first, localise thoughtfully, and stay anchored in mission whilst flexing their approach country by country. It’s the balance of global vision with local respect that allows organisations to scale sustainably.

How should health systems prepare today for demographic shifts such as ageing populations and declining fertility rates?

Health systems need to pivot toward longevity and lifelong health. That means shifting from treatment to prevention, integrating fertility into mainstream care, investing in automation, and building data systems that support people across decades.

We also need to rethink how we view ageing. It shouldn’t be seen as a burden but as an opportunity. Societies must encourage older adults to stay engaged — whether through work, part‑time roles, or volunteering — and design services, products, and especially financial tools that support high‑quality healthcare throughout a longer life.

As a returning judge for the Healthcare Asia Awards 2026, what capabilities do you value most when evaluating innovative healthcare leaders or solutions?

I look for leaders and solutions that create measurable, real‑world impact at scale. Evidence, sustainability, and a clear pathway to equitable access are essential. Creativity matters, but disciplined execution is what truly transforms healthcare.